多发性骨髓瘤-话题@MedSci

#多发性骨髓瘤#

50篇内容 | 7264人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1239346, encodeId=36191239346d7, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>虽然在过去10-15年多发性骨髓瘤 (MM) 疗法取得了显著进步，但 5 年相对生存率仍只有55.6%。在2期ELOQUENT-3试验中，与泊马度胺/地塞米松 (Pd) 相比，埃罗妥珠单抗联合泊马度胺/地塞米松 (EPd) 显著改善了既往接受来那度胺和蛋白酶体抑制剂（PI）治疗过的复发/难治性多发性骨髓瘤 (RRMM) 患者的无进展生存期 (PFS)。本文报告了该试验最终的总生存期（OS）结果。, objectTitle=多发性骨髓瘤, objectType=topic, longId=43116, objectId=null, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020121/1606821359582_4754896.jpg, objectUrl=null, replyNumber=0, likeNumber=85, createdTime=2022-08-17, rootId=0, userName=yangchou, userId=88b489038, projectId=1, avatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1222743, encodeId=b9181222e43e6, content=<a href='/topic/show?id=7f389396e27' target=_blank style='color:#2F92EE;'>#达雷妥尤单抗#</a>+<a href='/topic/show?id=518761566e4' target=_blank style='color:#2F92EE;'>#来那度胺#</a>一线治疗不适移植的<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>的疗效可期！, objectTitle=Lancet oncol：3期| 达雷妥尤单抗+来那度胺一线治疗不适移植的多发性骨髓瘤的疗效可期！, objectType=article, longId=218592, objectId=454b218592dd, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20211015/1634282603340_2570354.jpg, objectUrl=/article/show_article.do?id=454b218592dd, replyNumber=0, likeNumber=144, createdTime=2022-05-27, rootId=0, userName=清风徐来2022, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=454b218592dd, moduleTitle=Lancet oncol：3期| 达雷妥尤单抗+来那度胺一线治疗不适移植的多发性骨髓瘤的疗效可期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=454b218592dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1222742, encodeId=c20d1222e4279, content=<a href='/topic/show?id=ff1c3654ebf' target=_blank style='color:#2F92EE;'>#卡非佐米#</a>+<a href='/topic/show?id=518761566e4' target=_blank style='color:#2F92EE;'>#来那度胺#</a>+地塞米松继以来那度胺维持可有效预防高危<a href='/topic/show?id=cce030e1225' target=_blank style='color:#2F92EE;'>#冒烟型骨髓瘤#</a>进展成<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>, objectTitle=JAMA Oncol：卡非佐米+来那度胺+地塞米松继以来那度胺维持可有效预防高危冒烟型骨髓瘤进展成多发性骨髓瘤, objectType=article, longId=217541, objectId=850e21e541b6, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2021923/1632373620224_2110107.JPG, objectUrl=/article/show_article.do?id=850e21e541b6, replyNumber=0, likeNumber=196, createdTime=2022-05-27, rootId=0, userName=清风徐来2022, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=850e21e541b6, moduleTitle=JAMA Oncol：卡非佐米+来那度胺+地塞米松继以来那度胺维持可有效预防高危冒烟型骨髓瘤进展成多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=850e21e541b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1222741, encodeId=a57f1222e417a, content=<a href='/topic/show?id=518761566e4' target=_blank style='color:#2F92EE;'>#来那度胺#</a>+地塞米松±<a href='/topic/show?id=bba0415e798' target=_blank style='color:#2F92EE;'>#埃罗妥珠单抗#</a>治疗新发<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>, objectTitle=Lancet Haematol：来那度胺+地塞米松±埃罗妥珠单抗治疗新发多发性骨髓瘤, objectType=article, longId=727533, objectId=00e0e275331f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220521/1653145725078_2110107.JPG, objectUrl=/article/show_article.do?id=00e0e275331f, replyNumber=0, likeNumber=148, createdTime=2022-05-27, rootId=0, userName=清风徐来2022, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00e0e275331f, moduleTitle=Lancet Haematol：来那度胺+地塞米松±埃罗妥珠单抗治疗新发多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00e0e275331f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1215988, encodeId=7e3012159882c, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>, objectTitle=麻醉探秘 | 多发性骨髓瘤是怎么增加局麻药全身毒性反应发生风险的, objectType=article, longId=725848, objectId=ec72e258487e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220429/1651242551120_5635644.png, objectUrl=/article/show_article.do?id=ec72e258487e, replyNumber=0, likeNumber=122, createdTime=2022-05-01, rootId=0, userName=赛华佗, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec72e258487e, moduleTitle=麻醉探秘 | 多发性骨髓瘤是怎么增加局麻药全身毒性反应发生风险的, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec72e258487e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1206201, encodeId=9667120620142, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>, objectTitle=多发性骨髓瘤患者的VTE风险评估（IMPEDE VTE得分）, objectType=scale, longId=2598, objectId=2598, topicUrl=null, isHasObj=0, objectCover=https://static.medsci.cn/public-image/ms-image/c4014af0-a4f3-11ec-a1b8-6123b3ff61ea_企业微信截图_16472234662720.png, objectUrl=https://m.medsci.cn//scale/show.do?id=b9da259892, replyNumber=0, likeNumber=0, createdTime=2022-03-26, rootId=0, userName=医者仁者, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2598, moduleTitle=多发性骨髓瘤患者的VTE风险评估（IMPEDE VTE得分）, moduleType=scale, hrefUrl=https://m.medsci.cn/scale/show.do?id=b9da259892)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1206181, encodeId=b7eb1206181ee, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>, objectTitle=多发性骨髓瘤(MM)Durie-Salmon分期, objectType=scale, longId=2808, objectId=2808, topicUrl=null, isHasObj=0, objectCover=https://static.medsci.cn/public-image/ms-image/c4014af0-a4f3-11ec-a1b8-6123b3ff61ea_企业微信截图_16472234662720.png, objectUrl=https://m.medsci.cn//scale/show.do?id=1ef1280860, replyNumber=0, likeNumber=116, createdTime=2022-03-26, rootId=0, userName=医者仁者, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2808, moduleTitle=多发性骨髓瘤(MM)Durie-Salmon分期, moduleType=scale, hrefUrl=https://m.medsci.cn/scale/show.do?id=1ef1280860)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1198807, encodeId=31ac119880eb2, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>学习, objectTitle=多发性骨髓瘤, objectType=topic, longId=43116, objectId=null, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020121/1606821359582_4754896.jpg, objectUrl=null, replyNumber=0, likeNumber=111, createdTime=2022-03-02, rootId=0, userName=ms2000001939126778, userId=296a6497387, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1198395, encodeId=8ea4119839527, content=<a href='/topic/show?id=85fa10446166' target=_blank style='color:#2F92EE;'>#西达基奥仑赛#</a><a href='/topic/show?id=3e26e794600' target=_blank style='color:#2F92EE;'>#细胞治疗#</a>，这个厉害，<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>就成为了慢病了！总缓解率(ORR)高达98%(95%CI：92.7-99.7)，78%的患者获得了严格的完全反应(sCR，95%CI：68.8-86.1)。在18个月的中位随访时间中，中位缓解持续时间(DOR)为21.8个月(95% CI，21.8-无法预估)。估计随着随访时间延长，未来可能会更长！大量患者获得长期生存. 目前在美国定价为46.5万美元，还算便宜吧。在国内未来定位应该在80万人民币左右，这样就是平民价格了。, objectTitle=FDA批准传奇生物首款CAR-T细胞治疗产品CARVYKTI®(西达基奥仑赛)上市, objectType=article, longId=299876, objectId=e4402998e658, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20220228/08994fa1326a43f3a6325a7847e80f38.jpg, objectUrl=/article/show_article.do?id=e4402998e658, replyNumber=0, likeNumber=192, createdTime=2022-03-01, rootId=0, userName=医者仁者, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4402998e658, moduleTitle=FDA批准传奇生物首款CAR-T细胞治疗产品CARVYKTI®(西达基奥仑赛)上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4402998e658)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1196667, encodeId=7810119666ec5, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>学习, objectTitle=多发性骨髓瘤, objectType=topic, longId=43116, objectId=null, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020121/1606821359582_4754896.jpg, objectUrl=null, replyNumber=0, likeNumber=96, createdTime=2022-02-24, rootId=0, userName=ms9000000046672090, userId=510d5710114, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1180920, encodeId=76341180920a7, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>学习, objectTitle=多发性骨髓瘤, objectType=topic, longId=43116, objectId=null, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020121/1606821359582_4754896.jpg, objectUrl=null, replyNumber=0, likeNumber=92, createdTime=2022-01-05, rootId=0, userName=时也, userId=438a5513819, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1180919, encodeId=27b6118091951, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>学习, objectTitle=多发性骨髓瘤, objectType=topic, longId=43116, objectId=null, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020121/1606821359582_4754896.jpg, objectUrl=null, replyNumber=0, likeNumber=98, createdTime=2022-01-05, rootId=0, userName=时也, userId=438a5513819, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1060799, encodeId=623e1060e99c9, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>达雷妥尤单抗联合来那度胺和地塞米松相比单用来那度胺和地塞米松可延长不适合进行干细胞移植的新确诊的多发性骨髓瘤患者的总生存期和无进展生存期。无新的安全性事件发生。该研究结果支持在一线使用达雷妥尤单抗+来那度胺和地塞米松治疗不适合移植的多发性骨髓瘤患者。, objectTitle=多发性骨髓瘤, objectType=topic, longId=43116, objectId=null, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020121/1606821359582_4754896.jpg, objectUrl=null, replyNumber=0, likeNumber=148, createdTime=2021-10-15, rootId=0, userName=yangchou, userId=88b489038, projectId=1, avatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=969772, encodeId=7868969e7234, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>CAR-T治疗多发性骨髓瘤会不会进一步加深MM的缓解深度, objectTitle=多发性骨髓瘤, objectType=topic, longId=43116, objectId=null, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020121/1606821359582_4754896.jpg, objectUrl=null, replyNumber=1, likeNumber=136, createdTime=2021-05-31, rootId=0, userName=14674335m17暂无昵称, userId=fa565140002, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=955330, encodeId=14d29553309b, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>哪里可以看到相关最新资讯, objectTitle=多发性骨髓瘤, objectType=topic, longId=43116, objectId=null, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020121/1606821359582_4754896.jpg, objectUrl=null, replyNumber=2, likeNumber=140, createdTime=2021-04-08, rootId=0, userName=yqbs11, userId=cfc12612169, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1053477, encodeId=c27a10534e7c6, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>, objectTitle=Clin Cancer Res：多发性骨髓瘤患者进行CAR T细胞治疗时可安全应用桥接放疗！, objectType=article, longId=217385, objectId=eeaf21e38561, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2021920/1632150460555_2110107.JPG, objectUrl=/article/show_article.do?id=eeaf21e38561, replyNumber=0, likeNumber=149, createdTime=2021-09-21, rootId=0, userName=病毒猎手, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eeaf21e38561, moduleTitle=Clin Cancer Res：多发性骨髓瘤患者进行CAR T细胞治疗时可安全应用桥接放疗！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eeaf21e38561)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1052145, encodeId=9ba310521458c, content=<a href='/topic/show?id=5655104409bd' target=_blank style='color:#2F92EE;'>#达雷妥单抗#</a>维持治疗长达两年相比只是随访观察可显著降低<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>患者的疾病进展及死亡风险。, objectTitle=Lancet Oncol：达雷妥尤单抗维持治疗可显著降低多发性骨髓瘤患者的疾病进展及死亡风险, objectType=article, longId=217213, objectId=d65521e213ea, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2021916/1631781391582_2110107.png, objectUrl=/article/show_article.do?id=d65521e213ea, replyNumber=0, likeNumber=143, createdTime=2021-09-16, rootId=0, userName=病毒猎手, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d65521e213ea, moduleTitle=Lancet Oncol：达雷妥尤单抗维持治疗可显著降低多发性骨髓瘤患者的疾病进展及死亡风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d65521e213ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=999719, encodeId=e629999e1985, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>治疗进展, objectTitle=多发性骨髓瘤, objectType=topic, longId=43116, objectId=null, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020121/1606821359582_4754896.jpg, objectUrl=null, replyNumber=0, likeNumber=97, createdTime=2021-07-15, rootId=0, userName=ms4000000408264698, userId=e5185543565, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=966468, encodeId=d3a89664686b, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>多发性骨髓瘤的治疗需要进一步研究, objectTitle=多发性骨髓瘤, objectType=topic, longId=43116, objectId=null, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020121/1606821359582_4754896.jpg, objectUrl=null, replyNumber=0, likeNumber=140, createdTime=2021-05-18, rootId=0, userName=1903329706, userId=24324873661, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=964112, encodeId=e70e9641122a, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>多发性骨髓瘤与原发性淀粉样变性的区别, objectTitle=多发性骨髓瘤, objectType=topic, longId=43116, objectId=null, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020121/1606821359582_4754896.jpg, objectUrl=null, replyNumber=0, likeNumber=131, createdTime=2021-05-09, rootId=0, userName=hjhf, userId=88c54874945, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

多发性骨髓瘤

2020-05-29

yangchou (审核中...)

前往app查看评论内容

全文收起 #多发性骨髓瘤#虽然在过去10-15年多发性骨髓瘤 (MM) 疗法取得了显著进步，但 5 年相对生存率仍只有55.6%。在2期ELOQUENT-3试验中，与泊马度胺/地塞米松 (Pd) 相比，埃罗妥珠单抗联合泊马度胺/地塞米松 (EPd) 显著改善了既往接受来那度胺和蛋白酶体抑制剂（PI）治疗过的复发/难治性多发性骨髓瘤 (RRMM) 患者的无进展生存期 (PFS)。本文报告了该试验最终的总生存期（OS）结果。

2022-08-17

清风徐来2022 (审核中...)

前往app查看评论内容

#达雷妥尤单抗#+#来那度胺#一线治疗不适移植的#多发性骨髓瘤#的疗效可期！

Lancet oncol：3期| 达雷妥尤单抗+来那度胺一线治疗不适移植的多发性骨髓瘤的疗效可期！

2022-05-27

清风徐来2022 (审核中...)

前往app查看评论内容

#卡非佐米#+#来那度胺#+地塞米松继以来那度胺维持可有效预防高危#冒烟型骨髓瘤#进展成#多发性骨髓瘤#

JAMA Oncol：卡非佐米+来那度胺+地塞米松继以来那度胺维持可有效预防高危冒烟型骨髓瘤进展成多发性骨髓瘤

2022-05-27

清风徐来2022 (审核中...)

前往app查看评论内容

#来那度胺#+地塞米松±#埃罗妥珠单抗#治疗新发#多发性骨髓瘤#

Lancet Haematol：来那度胺+地塞米松±埃罗妥珠单抗治疗新发多发性骨髓瘤

2022-05-27

赛华佗 (审核中...)

前往app查看评论内容

#多发性骨髓瘤#

麻醉探秘 | 多发性骨髓瘤是怎么增加局麻药全身毒性反应发生风险的

2022-05-01

医者仁者 (审核中...)

前往app查看评论内容

#多发性骨髓瘤#

多发性骨髓瘤患者的VTE风险评估（IMPEDE VTE得分）

2022-03-26

医者仁者 (审核中...)

前往app查看评论内容

#多发性骨髓瘤#

多发性骨髓瘤(MM)Durie-Salmon分期

2022-03-26

ms2000001939126778 (审核中...)

前往app查看评论内容

#多发性骨髓瘤#学习

2022-03-02

医者仁者 (审核中...)

前往app查看评论内容

全文收起 #西达基奥仑赛##细胞治疗#，这个厉害，#多发性骨髓瘤#就成为了慢病了！总缓解率(ORR)高达98%(95%CI：92.7-99.7)，78%的患者获得了严格的完全反应(sCR，95%CI：68.8-86.1)。在18个月的中位随访时间中，中位缓解持续时间(DOR)为21.8个月(95% CI，21.8-无法预估)。估计随着随访时间延长，未来可能会更长！大量患者获得长期生存. 目前在美国定价为46.5万美元，还算便宜吧。在国内未来定位应该在80万人民币左右，这样就是平民价格了。

FDA批准传奇生物首款CAR-T细胞治疗产品CARVYKTI®(西达基奥仑赛)上市

2022-03-01

ms9000000046672090 (审核中...)

前往app查看评论内容

#多发性骨髓瘤#学习

2022-02-24

时也 (审核中...)

前往app查看评论内容

#多发性骨髓瘤#学习

2022-01-05

时也 (审核中...)

前往app查看评论内容

#多发性骨髓瘤#学习

2022-01-05

yangchou (审核中...)

前往app查看评论内容

#多发性骨髓瘤#达雷妥尤单抗联合来那度胺和地塞米松相比单用来那度胺和地塞米松可延长不适合进行干细胞移植的新确诊的多发性骨髓瘤患者的总生存期和无进展生存期。无新的安全性事件发生。该研究结果支持在一线使用达雷妥尤单抗+来那度胺和地塞米松治疗不适合移植的多发性骨髓瘤患者。

2021-10-15

14674335m17暂无昵称 (审核中...)

前往app查看评论内容

#多发性骨髓瘤#CAR-T治疗多发性骨髓瘤会不会进一步加深MM的缓解深度

2021-05-31

yqbs11 (审核中...)

前往app查看评论内容

#多发性骨髓瘤#哪里可以看到相关最新资讯

2021-04-08

病毒猎手 (审核中...)

前往app查看评论内容

#多发性骨髓瘤#

Clin Cancer Res：多发性骨髓瘤患者进行CAR T细胞治疗时可安全应用桥接放疗！

2021-09-21

病毒猎手 (审核中...)

前往app查看评论内容

#达雷妥单抗#维持治疗长达两年相比只是随访观察可显著降低#多发性骨髓瘤#患者的疾病进展及死亡风险。

Lancet Oncol：达雷妥尤单抗维持治疗可显著降低多发性骨髓瘤患者的疾病进展及死亡风险

2021-09-16

ms4000000408264698 (审核中...)

前往app查看评论内容

#多发性骨髓瘤#治疗进展

2021-07-15

1903329706 (审核中...)

前往app查看评论内容

#多发性骨髓瘤#多发性骨髓瘤的治疗需要进一步研究

2021-05-18

hjhf (审核中...)

前往app查看评论内容

#多发性骨髓瘤#多发性骨髓瘤与原发性淀粉样变性的区别

2021-05-09

科室
- - 订阅+
  - 更多科室
工具
服务